EU Agrees to Buy Potential Sanofi, GSK Covid-19 Vaccine
September 18 2020 - 7:39AM
Dow Jones News
By Mauro Orru
The European Commission said Friday that it has signed a
contract with Sanofi SA and GlaxoSmithKline PLC to secure up to 300
million doses of their potential Covid-19 vaccine.
The commission, the EU's executive arm, didn't disclose
financial details but said the contract marks the second deal the
EU has struck for the supply of vaccines against coronavirus,
following a deal it already signed with British drug maker
AstraZeneca PLC.
"Agreements with other companies will be concluded soon and
build a diversified portfolio of promising vaccines, based on
various types of technologies, increasing our chances to find an
effective remedy against the virus," European Commission President
Ursula von der Leyen said.
Sanofi and GSK aim to have the vaccine available by the second
half of 2021, after starting a Phase 1 and 2 study in September,
with a Phase 3 study by the end of 2020.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
September 18, 2020 07:24 ET (11:24 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
